While it may seem counter-intuitive to treat an autoimmune disease with self-reactive autoantibodies, Acorda Therapeutics Inc. is a step closer to entering the clinic with just such a hypothesis. The company believes that it has identified a class of human autoantibodies that can promote healing of the central nervous system.

Acorda collaborators at the Mayo Clinic (Rochester, Minn.) last week published in the Proceedings of the National Academy of Sciences that two human monoclonal antibodies against oligodendrocyte surface antigens promoted remyelination of neurons in a mouse model of MS.